Early observations and pilot data that first suggested a new direction
The identification of H. pylori by Marshall and Warren as the cause of peptic ulcers led to the development of eradication regimens. Standard PPI-based triple therapy (PPI + clarithromycin + amoxicillin for 7-14 days) became the mainstay. The Maastricht I Consensus in 1996 and subsequent iterations established the framework for test-and-treat strategies, emphasizing that H. pylori eradication could cure peptic ulcer disease, reduce gastric cancer risk, and prevent NSAID ulcer recurrence.
Landmark RCTs and pivotal trials that established the evidence base
Declining eradication rates with standard triple therapy (below 80% in many regions) drove the search for alternatives. Bismuth quadruple therapy and concomitant quadruple therapy emerged as options for areas with high clarithromycin resistance. The Maastricht VI/Florence Consensus in 2022 formally recommended susceptibility-guided therapy over empiric treatment whenever possible, and mandated 14-day treatment durations. This represented a fundamental shift from one-size-fits-all empiric therapy to personalized, resistance-aware treatment.
Follow-up studies, subgroup analyses, and real-world validation
The pHalcon-HP trial introduced vonoprazan, a potassium-competitive acid blocker (P-CAB), as a replacement for PPIs in eradication regimens. Vonoprazan provides faster, more potent, and more stable acid suppression than PPIs, potentially improving antibiotic efficacy. In the phase 3 trial, vonoprazan-based triple therapy achieved comparable eradication rates to lansoprazole-based therapy overall, but notably higher rates in clarithromycin-resistant strains. The FDA approved vonoprazan-based regimens for H. pylori eradication in 2022.
Integration into clinical practice guidelines and recommendations
The Maastricht VI consensus and ACG 2017 guidelines emphasized local resistance data to guide empiric regimen choice, with bismuth quadruple therapy recommended where clarithromycin resistance exceeds 15%. Both advocated 14-day treatment courses and post-treatment eradication confirmation at least 4 weeks after therapy completion. Vonoprazan-based regimens were incorporated as alternatives to PPI-based approaches.
Maastricht VI
Susceptibility-guided therapy preferred; 14-day treatment; bismuth quadruple therapy for high clarithromycin resistance regions
ACG
14-day PPI triple therapy or bismuth quadruple therapy based on local resistance; confirm eradication 4 weeks post-treatment
Now
Current standard of care and ongoing research directions
H. pylori management has shifted from empiric triple therapy to a resistance-informed, regionally adapted approach. The availability of vonoprazan offers a new acid suppression platform. Key challenges include antibiotic resistance surveillance, accessibility of susceptibility testing, declining eradication rates with empiric therapy, and the need for simplified, high-efficacy regimens. The link between H. pylori eradication and gastric cancer prevention continues to strengthen, particularly in high-incidence populations.
Why has standard triple therapy become less effective?+
Clarithromycin resistance has risen to 15-30% in many regions, reducing standard PPI-clarithromycin-amoxicillin triple therapy efficacy below 80%. The Maastricht VI consensus now recommends against empiric clarithromycin-based triple therapy in areas with resistance >15%, favoring bismuth quadruple therapy or susceptibility-guided regimens instead.
What is vonoprazan and how does it differ from PPIs?+
Vonoprazan is a potassium-competitive acid blocker (P-CAB) that achieves faster, more potent, and more consistent acid suppression than PPIs. Unlike PPIs, it does not require acid activation and provides immediate effect. In the pHalcon-HP trial, vonoprazan-based triple therapy achieved 84.7% eradication overall and showed particular benefit in clarithromycin-resistant strains.
